Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With SoRbitol Dehydrogenase (SORD) DEficiency

NCT05397665 is registered in ClinicalTrials.gov with Applied Therapeutics, Inc. as lead sponsor.

NCT NCT05397665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05397665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With SoRbitol Dehydrogenase (SORD) DEficiency
Lead sponsor
Applied Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
January 1, 2022
Completion date
June 1, 2026
Enrollment
56 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary neuropathy caused by sord deficiency